What people are reporting about GHRP-2, GHRP-6, and Hexarelin

There's a particular flavor of thread that surfaces regularly on forums like r/peptides and r/PEDs — the person who started with GHRP-6 or GHRP-2 years ago, before Ipamorelin became the default recommendation, before MK-677 was widely available, and who has opinions. Strong ones, often. The older secretagogues have an older-guard community around them: people who used these compounds when the choices were different, whose experiences with them predate the current landscape, and who sometimes push back on the consensus that the newer compounds are straightforwardly superior. That community is part of what this article is trying to document.

Before going further, the structural caveat is necessary: online communities self-select in ways that create systematic positivity bias. People who had bad experiences are less likely to keep posting. People who had no noticeable effect often don't report it at all. The people who are most enthusiastic are also the most likely to be vocal. What circulates in these spaces is not a representative sample of everyone who has used these compounds — it's a sample of people motivated enough to share, filtered through a community culture that tends to reward positive reports with engagement. This matters when reading anything that follows.

The appetite discussion is probably the single most consistent theme across the older-secretagogue communities, and it splits cleanly by application. For the group using these compounds for body-composition goals — leaner, more muscular, more recovered — the appetite stimulation of GHRP-6, and to a lesser degree GHRP-2, is almost universally described as a complication. Reports on cutting cycles with GHRP-6 consistently mention the hunger as a practical obstacle: the compound is producing GH stimulation, the GH should be supporting fat mobilization and lean mass preservation, but the ghrelin-mimetic hunger signal makes caloric restriction substantially harder. A recurring pattern in these threads is people switching from GHRP-6 to GHRP-2 mid-cycle because the appetite drive became unmanageable, or switching to Ipamorelin for the same reason.

The opposite report is equally consistent in a different subcommunity. People pursuing weight gain — hardgainers who genuinely struggle to eat enough, people recovering from illness or significant muscle loss — describe the GHRP-6 appetite stimulation as exactly what they needed. Reports in this context frame the hunger signal as the compound doing its job: increasing the desire to eat in conjunction with anabolic GH signaling. The same pharmacological property reads as a feature or a bug depending entirely on what the person needed going in. This is worth holding as an illustration of how individual context shapes compound experience in ways that make aggregate reporting limited in its usefulness.

The cortisol and prolactin awareness in these communities is more sophisticated than it was ten years ago, in part because the information environment has improved. Regular posters on r/peptides now routinely mention the cortisol elevation pattern of GHRP-2 and GHRP-6 as a consideration, and lab-checking for morning cortisol before and during a cycle is commonly recommended in pinned resources and experienced-user responses to newcomer questions. The actual impact of the cortisol elevation on outcomes — whether it meaningfully offsets the GH-related benefits in body-composition protocols — is genuinely contested in these discussions. Some experienced users report noticing no negative effects attributable to cortisol during GHRP-2 cycles. Others report the opposite. The honest answer, which some threads arrive at, is that individual HPA-axis reactivity is variable enough that neither universal reassurance nor universal concern is appropriate.

Hexarelin's community is a narrower and somewhat more specialized subset. The compound attracts users who are specifically interested in its potency — people who have found Ipamorelin underwhelming in terms of GH pulse size, or who want a short, high-amplitude pulse for a defined period rather than the more sustained moderate stimulation of a daily Ipamorelin or GHRP-2 protocol. The desensitization problem is widely understood in this community, often discussed in the same breath as the compound's name. The cycling protocols that have emerged — two to four weeks on, four to six weeks off, sometimes longer off-periods — are community-derived, not clinically established, and vary significantly between individual reports. The general principle (the receptor needs time to resensitize; continuous use defeats the purpose) is consistent. The specific timing is not.

Some reports describe using Hexarelin in short-cycle blasts: a two-week period of daily or twice-daily use aimed at a specific goal — recovery from injury, a preparatory phase before a demanding physical period — followed by a complete break. This use pattern attempts to capture Hexarelin's potency in a window short enough to avoid significant desensitization. Whether it works as described is difficult to assess from community reports alone, because the subjective markers people use — felt energy, sleep quality, recovery rate — are poor proxies for actual GH pulse magnitude, and few people are running IGF-1 labs closely enough to quantify the receptor adaptation curve.

The comparison between older GHRPs and Ipamorelin is one of the most reliably recurring threads, and the community consensus has largely settled in a place that the clinical literature would broadly support: Ipamorelin is cleaner, more predictable, and more appropriate for sustained body-composition protocols; the older GHRPs are messier, have more off-target effects, and are harder to use well. The characterization of Ipamorelin as "cleaner but less potent" than GHRP-2 is common and roughly accurate, with the understanding that "less potent" in this context means the GH pulse is somewhat smaller, not that the compound is without meaningful effect.

Price enters the conversation consistently enough to be worth documenting. GHRP-2 and GHRP-6 are generally reported as cheaper per milligram than Ipamorelin, sometimes significantly so depending on supplier and formulation. For people self-funding extended peptide protocols and working within a budget, this cost differential is a real factor. Threads in the "what do I use when money matters" category — a recognizable and practical genre in these forums — frequently surface GHRP-2 as a reasonable second choice when Ipamorelin pricing is prohibitive. The trade-off framing is common: you're accepting more cortisol and more appetite stimulation in exchange for lower cost, and whether that trade is acceptable depends on your goals and your physiology.

A smaller but consistent thread discusses these compounds in the context of GH deficiency and recovery from significant health events — illness, surgery, severe stress periods. People in these situations describe using GHRP-2 or GHRP-6 during recovery phases specifically because the appetite stimulation is a benefit rather than a problem: they're trying to eat more, sleep better, and rebuild physical capacity after something that depleted them. The reports in this context tend to be measured, specific about the health context, and notably less focused on performance metrics than the body-composition threads. This subcommunity's experience may actually be the most clinically coherent application of these compounds, closest to the cachexia and wasting-disease research that originally motivated their development.

What's missing from the community conversation, consistently, is rigorous biomarker tracking. Lab data showing IGF-1 before and after, cortisol curves, prolactin levels — these come up occasionally in experienced-user discussions and are recommended by the better-informed moderators and contributors, but they're not the norm. The bulk of the reporting is symptom-based and subjective. Better sleep, faster recovery, more energy, increased appetite, changes in body composition over months — real experiences, genuinely reported, but difficult to interpret without the objective anchors that would let you distinguish a meaningful physiological response from a placebo effect, a lifestyle change, or natural variation. The community knows this, at least in part. The better threads say so.

None of what's described here constitutes evidence for the efficacy or safety of GHRP-2, GHRP-6, or Hexarelin. These compounds are not FDA-approved for any indication. The experiences reported in online communities are exactly that — reported experiences, filtered through selection bias, described in subjective terms, and shared without clinical oversight. They're worth understanding because they represent a real public conversation that has been happening for decades, and because that conversation shapes how people approach these compounds regardless of whether the scientific literature has caught up with every question it raises. But this is a description of what people are saying, not an assessment of what they should do. That assessment belongs in a clinical conversation, with a prescribing provider, built on an individual's actual health picture.